Get notified when RARE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Investors Purchasing Shares of Common Stock or Pre-funded Warrants In This Offering Will Incur Immediate Dilution of $36.11 Per Share (new) — The offering price is far above the as-adjusted net tangible book value, causing substantial immediate dilution to new investors.
- There Is No Established Public Trading Market For the Pre-funded Warrants Being Offered In This Offering, and We Do Not Expect a Market to Develop. (new) — Pre-funded warrant holders may be unable to sell their warrants and can only realize value by exercising them into common stock.
Ultragenyx prices $350M offering of 7.4M shares and pre-funded warrants at $39.00
Filed June 14, 2024 · ~1 min read
Key Changes
-
high
Ultragenyx is selling 7,435,898 common shares and pre-funded warrants for 1,538,501 shares at $39.00 per share, raising $331.2M before expenses.
The Offering verify on EDGAR → -
high
Net proceeds to the company are estimated at $330.7M, or $380.4M if underwriters fully exercise their option to buy 1,346,153 additional shares.
Use of Proceeds verify on EDGAR → -
high
Proceeds will fund late-stage clinical programs, global commercial launches, preclinical pipeline advancement, and potential acquisitions or in-licensing.
Use of Proceeds verify on EDGAR →
4 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SAR 10-Q) is open in full — no account needed.
Partner
Trade RARE commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify